

Vigna Law Group: Depo-Provera Meningioma Claim Filed in Alameda County, California

Medical literature links continued Depo-Provera use after meningioma resection to higher recurrence, raising physician and manufacturer liability concerns

LOS ANGELES, CA, UNITED STATES, January 7, 2026 /EINPresswire.com/ -- "At some point, physicians can be held liable for prescribing Depo-Provera when there are alternative birth control medications that do not cause mutations that lead to brain tumors. The literature on this is clear," states Greg Vigna, MD, JD, national malpractice, Depo-Provera attorney.

Dr. Greg Vigna, MD, JD, says, "We filed this case because drug was not only prescribed before our client's meningioma diagnosis, but also continued after surgical removal of the tumor. We allege that our client's injuries were further exacerbated by the ongoing prescription, resulting in additional harm." (Case: 25CV151521, Superior Court of the State of California for the County of Alameda).



Dr. Greg Vigna

Dr. Vigna continues, "Clearly, women who are newly diagnosed and have a history of recent use should have their cases closely reviewed to determine whether their claims may be more appropriately filed against both the prescribing physician and the manufacturer of Depo-Provera or an authorized generic in state court where the injury occurred."

What does the literature say about continued use of Depo-Provera after resection?

Read Dr. Tessa Harland's report in "Progesterone-only contraception is associated with a shorter progression-free survival in premenopausal women with WHO Grade I meningioma" published in the Journal of Neuro-oncology (2018) 136:327-333?:

"Compared to patients taking combination or estrogen-only contraception, those taking progesterone-only contraception demonstrated a greater recurrence rate (33.3 vs. 19.6%) with a

reduced time to recurrence (18 vs. 32 months, $p = 0.038$) ... those taking progesterone-only contraception."

Read Dr. Harland's article [here](#).

Dr. Vigna concludes, "There have always been safer medications for contraception than Depo-Provera. This is a drug that causes specific mutations to women's DNA."

10	SUPERIOR COURT OF THE STATE OF CALIFORNIA	
11	FOR THE COUNTY OF ALAMEDA	
12	SAADA TAPPIN,	Case No.: <u>25CV151521</u>
13	<i>Plaintiff,</i>	COMPLAINT FOR DAMAGES FOR:
14	v.	1. NEGLIGENCE (FAILURE TO WARN)
15	CHRISTIE COOKSEY, M.D.; KAISER	2. MEDICAL NEGLIGENCE
16	FOUNDATION HEALTH PLAN INC.;	 <u>JURY TRIAL DEMANDED</u>
17	KAISER FOUNDATION HOSPITALS;	
18	THE PERMANENTE MEDICAL	
19	GROUP, INC.; and DOES 1-25, Inclusive,	
20	<i>Defendants.</i>	

Case: 25CV151521

Watch Dr. Vigna's [educational episode](#) on Justice with Dr. V for an in-depth look at the association of Depo-Provera and Meningiomas.

[Click here](#) to watch Justice with Dr. V on Tik Tok to learn more on Depo-Provera.



We filed this case because drug was not only prescribed before our client's meningioma diagnosis, but also continued after surgical removal of the tumor."

Greg Vigna, MD, JD

Dr. Vigna is a California and Washington DC lawyer and is Co-Counsel with the Ben Martin Law Group, a national pharmaceutical injury law firm in Dallas, Texas. The attorneys are product liability and medical malpractice attorneys, and they represent women who have suffered meningiomas.

To learn more, visit <https://vignallawgroup.com/practice-area/meningioma-resection/>.

Case: 25CV151521

Superior Court of the State of California for the County of Alameda

California Offices:

8939 S. Sepulveda Blvd., Suite 102, Los Angeles, CA 90045

2570 N. First Street, 2nd Floor, San Jose, CA 95131

931 10th Street, #962, Modesto, CA 95354

2281 Lava Ridge Court, Suite 200, Roseville, CA 95661

600 West Broadway, Suite 700, San Diego, CA 92101

Connecticut Office:

515 Centerpoint Drive, Suite #2212, Middletown, CT 06457

Greg Vigna, MD, JD

Vigna Law Group

+1 817-809-9023

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/880978681>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.